Common questions about Zerbaxa (FAQ)
Q: Is Zerbaxa considered a new generation antibiotic?
A: Regulatory documents describe Zerbaxa as a combination drug containing ceftolozane, an extended-spectrum cephalosporin antibacterial, and tazobactam, which is a beta-lactamase inhibitor. This formulation is designed to work against certain resistant Gram-negative bacteria.
Q: Is it possible to receive Zerbaxa outside of a hospital setting, such as in an outpatient clinic?
A: While Zerbaxa is typically administered in a hospital setting due to the serious nature of the infections it treats, official information indicates that its use can occur within Outpatient Parenteral Antimicrobial Therapy (OPAT) services. Its required intravenous administration ensures it is delivered in a supervised healthcare environment.
Q: Is Zerbaxa a controlled substance?
A: Official governmental sources confirm that Zerbaxa is classified as a prescription-only medicine. It is not currently designated as a controlled substance under regulatory acts like the U.S. Controlled Substances Act (CSA).
Q: Can Zerbaxa cause a severe drop in blood pressure (hypotension)?
A: Hypotension (low blood pressure) has been reported as an adverse reaction in clinical trials. Monitoring is typically part of the standard care when this medicine is administered. The product label notes that this event is considered uncommon.
Q: Is a generic version of Zerbaxa available on the market?
A: No. According to current official drug databases and patent information, a generic version of Zerbaxa (ceftolozane/tazobactam) is not currently available in the United States or the European Union.
Q: What is the difference between ceftolozane and ceftazidime?
A: Ceftolozane is officially classified as an extended-spectrum cephalosporin. Regulatory and in vitro data indicate that the ceftolozane component of Zerbaxa, when combined with tazobactam, is noted to have potent activity against certain resistant bacterial strains, particularly Pseudomonas aeruginosa, compared to ceftazidime.
Q: Can patients who have received other antibiotics in the past still be treated with Zerbaxa?
A: Regulatory guidelines describe that to help maintain the effectiveness of Zerbaxa and other antibacterial drugs, the medicine is intended to be used only for infections that are proven or strongly suspected to be caused by susceptible bacteria. This standard practice is intended to minimize the risk of developing resistance.
Q: How quickly does Zerbaxa clear out of the body in a patient with normal kidney function?
A: Pharmacokinetic data from official sources indicate the medicine clears from the body relatively quickly in patients with normal kidney function. The half-life, which is the time it takes for half the drug to be eliminated, is approximately 2.77 hours for ceftolozane and approximately 0.91 hours for tazobactam.
Q: Are there any specific safety precautions for patients with a history of seizures when using Zerbaxa?
A: The official product labeling notes that seizures and other central nervous system effects have occurred with the use of this class of antibiotics (beta-lactams). As with this class of antibiotics, monitoring for central nervous system effects is a standard procedure during administration.
Q: Can the administration of Zerbaxa cause irritation or inflammation at the IV site (phlebitis)?
A: Yes, infusion site reactions are reported in the official adverse reactions section. Venous thrombosis (a blood clot in the vein) and other signs of local irritation or inflammation (phlebitis) have been noted as uncommon side effects.
Q: What is the purpose of the liquid (diluent) used to mix Zerbaxa for IV administration?
A: Zerbaxa is supplied as a sterile powder. A diluent, such as sterile water or 0.9% Sodium Chloride solution, is first used to reconstitute the powder, dissolving it completely. The solution is then further diluted before being slowly infused into the vein over one hour.
Q: What does 'ventilator-associated bacterial pneumonia' (VABP) mean in relation to Zerbaxa's use?
A: VABP is an official indication for Zerbaxa, meaning it is approved for this type of infection. VABP is described as a serious lung infection that develops in hospitalized patients who are receiving breathing support from a mechanical ventilator.
Q: Does Zerbaxa affect blood cell components, such as causing a low neutrophil count (neutropenia)?
A: Regulatory information indicates that changes in certain blood cell components have been observed. For instance, increases in platelets (thrombocytosis) and decreases in red blood cells (anemia) have been noted in clinical studies, particularly in pediatric patients.
Q: What is the risk of developing a fungal infection (like candidiasis) while on Zerbaxa?
A: Like many antibiotics, Zerbaxa can potentially alter the body's natural flora. The official adverse reaction data includes infections, such as candidiasis (yeast/fungal infection) and fungal urinary tract infection, as uncommon events.
